Navigation Links
China Large Volume Parenteral Industry (LVP) 2015 Forecasts in New Research Report at ChinaMarketResearchReports.com
Date:11/28/2013

Dallas, TX (PRWEB) November 29, 2013

Under the context of China's medical reform and sustainable development of the pharmaceutical market, the output and demand of Large Volume Parenteral (LVP) which is one of the top five Chinese preparations have grown year by year. In 2006-2012, China’s injection output presented the CAGR of 19.2%. However, due to the low barriers to entry, China has seen some signs of the surplus injection capacity, which exceeds the demand by roughly 40%.

Overcapacity and fierce competition are caused by the irrational injection product structure and homogeneity. For example, the output and sales volume of fluid balance injection products with low added value account for 89% of the injection market, but the sales revenue only shares 47%. At the same time, the market demand for amino acids, fat emulsion dual-chamber bags, fat emulsion, total parenteral nutrition, hydroxyethyl starch and unique traditional Chinese medicine injection is quite strong.

The complete report is available at http://www.chinamarketresearchreports.com/114669.html.

Compared to Europe and other developed countries, the concentration degree of Chinese LVP market is still lower. At present, 200 ones of 400 qualified Chinese LVP enterprises run business soundly. By output, the top 10 Chinese companies contribute about 65%; in terms of sales revenue, they devote about 40 %.

Like other chemical preparation segments, Chinese high-end LVP market is still dominated by foreign pharmaceutical companies such as Japan Otsuka, Germany Fresenius Kabi, and USA Baxter.

Take fat emulsion products for example. Fat emulsion is imported by China frequently as a blood and hematopoietic system drug in recent years, with its import volume having been at the high level of typical urban hospitals in 22 Chinese cities for consecutive years. Particularly, the procurement value of moderate and long-chain fat emulsion imported by Chinese typical hospitals hit RMB354million. In China, fat emulsion injection suppliers include Kelun Pharma, Sino-Swed Pharmaceutical Corp, Ltd. (under Fresenius Kabi) and Guangzhou Baxter Qiaoguang (under Baxter) with the respective output of 14.19 million bottles/bags, 8.1 million bottles / bags (including medium/long-chain fat emulsion) and 5.69 million bottles/bags (medium/long-chain fat emulsion) in 2012.

The report highlights the following:

  •     Status quo, competition patterns, product structure, regional distribution and development forecast of Chinese LVP market;
  •     Status quo and competition patterns of fluid balance injection, therapeutic injection, nutrition injection, injection for blood volume expansion and peritoneal dialysis fluid injection and other market segments;
  •     Operation, LVP business and prospects of 10 companies including Kelun Pharma, China Resources Double-Crane, Fengyuan Pharmaceutical, Huaren Pharmaceutical, Southwest Pharmaceutical and Lijun International Pharmaceutical.

Purchase a copy of this report at http://www.chinamarketresearchreports.com/contacts/purchase.php?name=114669.

Browse more reports on Life Sciences Industry at http://www.chinamarketresearchreports.com/cat/life-sciences.html.

About Us:
ChinaMarketResearchReports.com (http://www.chinamarketresearchreports.com/) is an online database of market research reports offers in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Read the full story at http://www.prweb.com/releases/large-volume-parenteral/lvp-industry-report-2013/prweb11378995.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Artisan Hosts US China India Investment Event August 23-24, 2012
2. New screening test to help people with hearing loss in China
3. Mahvrick Expands to Brazil, Russia, India, China to Support Existing Client Customer Growth
4. Child diabetes levels higher in China than in US, study finds
5. Mothers, children underestimate obesity in China
6. Environmental Monitoring in China Industry Research Report – Now Available from IBISWorld
7. Medical Research in China Industry Research Report – Now Available from IBISWorld
8. Global collaborative efforts help delineate pediatric TBI in China
9. Pigs in southern China infected with avian flu
10. Bioforce AG Announces Doctors Comments Showing Efficacy of Echinaforce for Immune Support Now On You Tube
11. Stakeholder Communities in China and Korea – by Heartbeat Experts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... ... May 23, 2016 , ... While new U.S. opioid ... physicians are not legally required to follow them. In the absence of federal ... Novus Medical Detox Center , a leading Florida-based drug treatment facility, strongly ...
(Date:5/23/2016)... ... ... the upcoming airing of Innovations with Ed Begley, Jr., ... 4:00pET via Fox Business. , The show will explore ... safely and rapidly develop cures for mosquito-borne, emerging infectious ...
(Date:5/23/2016)... , ... May 23, 2016 ... ... Size for Verification and Validation:, Tools to Safely Speed Your Device to ... http://www.fdanews.com/bestdevicesamplesizevv                  , Today's FDA inspectors focus like lasers on device ...
(Date:5/23/2016)... (PRWEB) , ... May 23, 2016 , ... ... the action analytics leader as Chief Medical Officer. Dr. O’Connor’s deep expertise in ... product development and client services teams who deliver best-in-class solutions and transformative technologies ...
(Date:5/23/2016)... Valley, California (PRWEB) , ... May 23, 2016 ... ... clinical communications and solutions for healthcare providers announced today that AGNITY MobileCare™ Platform ... and health collaboration applications as a part of its M-Health Solution. Tech Mahindra ...
Breaking Medicine News(10 mins):
(Date:5/19/2016)... Israel , May 19, 2016 ... the "Company"), an emerging global ophthalmic company focused on ... candidates which address ophthalmic conditions, announced today that it ... Italy ) for the manufacturing, distribution, marketing ... for the treatment of dry eye syndrome (DES) and ...
(Date:5/19/2016)... May 19, 2016 A ... World Biopsy Devices Market Opportunities and Forecasts, 2014 ... market generated $1,621 million in 2015. The MRI-guided ... and is expected to maintain this trend over ... http://photos.prnewswire.com/prnh/20140911/647229 ) , To know ...
(Date:5/19/2016)... BioLineRx Ltd. (NASDAQ/TASE: BLRX) announced ... of multiple cancer and hematological indications, will be presented ... titled " Clinical response in relapsed/refractory AML patients correlates ... a potent CXCR4 antagonist; results of a Phase 2a ... the European Hematology Association 21st Congress, to be held ...
Breaking Medicine Technology: